The company is up by 3.73 percent from yesterday’s close. It is trading at $39.44 a tad above $34.16, the stock’s 50 day moving average and barely above the 200 day moving average of $34.70. The 50 day moving average went up by +15.19% and the 200 day average moved up $4.65.
Traders are a little more bearish on shares of the company recently if you put credence in the rise in short interest. The firm saw a rise in short interest from June 15, 2017 to May 31, 2017 of 8.73%. Short interest grew from 571,885 to 621,839 over that timeframe. The days to cover increased to 5.7 and the percentage of shorted shares was 0.01% on May 31.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product which is in Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trials for the treatment of CMPA and milk-induced eosinophilic esophagitis; and Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy. Its other earlier stage product development programs include a booster vaccine for pertussis, as well as treatments for Crohn’s disease and respiratory syncytial virus. DBV Technologies S.A. has collaboration with NestlÃ© Health Science to develop and commercialize a novel diagnostic test for pediatric milk allergy. The company was founded in 2002 and is headquartered in Montrouge, France..
Here are a few additional firms who have increased or decreased their stake in (DBVT). Gw&k Investment Management, LLC cut its position by selling 2,517 shares a decrease of 2.4% in the quarter. Gw&k Investment Management, LLC currently owns 100,883 shares with a value of $3,603,000. The value of the position overall is down by 1.1%. As of the end of the quarter Morgan Stanley had bought 1,066 shares growing its position 38.8%. The value of the total investment in DBV Technologies S.A. – America went from $97,000 to $135,000 a change of 39.2% quarter over quarter.
Tower Research Capital LLC (trc) downsized its stake by shedding 486 shares a decrease of 74.3% as of 03/31/2017. Tower Research Capital LLC (trc) controls 168 shares worth $6,000. The total value of its holdings decreased 73.9%. Goldman Sachs Group Inc grew its holdings by buying 1,647 shares an increase of 3.1%. Goldman Sachs Group Inc claims 55,499 shares valued at $1,955,000. The total value of its holdings increased 3.3%.
On July 11 Morgan Stanley kept the company rating at “Overweight” and raised the price expectation from $59.00 to $67.00. March 16 investment analysts at Citigroup maintained a company rating of “Buy” but lowered the price target to $43.00 from $48.00.
Equity analyst Barclays began coverage of DBVT setting a rating of “Overweight” and a price target of $58.00. On September 15, 2015 Morgan Stanley starting coverage on the stock giving it an initial rating of “Overweight” and projecting a price target of $59.00.
August 11 investment analysts at Leerink Swann kept the stock rating at “Outperform” and raised the price target from $44.00 to $56.00. On March 18 analysts at H.C. Wainwright added the stock to its research portfolio with an initial rating of “Buy” and establishing a price target of $50.00.